Inflammation and Neurocognitive Damage Markers in Elderly People With Obstructive Sleep Apnea
NCT ID: NCT04882020
Last Updated: 2021-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
76 participants
OBSERVATIONAL
2019-08-21
2021-06-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Dementia in Chronic Sleep and Breathing Disorders
NCT06377332
Chronic Sleep Restriction
NCT01493661
Sleep Apnea and Cognitive Function in Subjects With Subjective or Mild Cognitive Impairment
NCT06089096
Sleep Disordered Breathing, APOE, and Lipid Metabolism
NCT00046670
Comparison of RT in Patients With Sleep Apnea With and Without Complaints of Daytime Sleepiness
NCT01562262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AHI ≤ 5
Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≤ 5 events / hour; prior blood collection between 7-9 am and questionnaires.
cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha
compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
AHI ≥ 30
Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≥ 30 events / hour; prior blood collection between 7-9 am and questionnaires.
cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha
compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha
compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* both sexes;
* free and informed consent form previously signed for participation in the MEDIDAS cohort study;
* previous performance of outpatient polysomnography with adequate technical quality
* AHI ≤ 5 or ≥ 30 events/hour;
* previous blood collection between 7-9 am; questionnaires.
Exclusion Criteria
* suffer from rheumatic or chronic diseases such as diabetes mellitus, heart failure, coronary artery disease, chronic renal failure or nephropathy (creatinine\> 1.8 mg / dL), liver disease, history of stroke, aortic aneurysm, marked elevation in blood arterial pressure (\> 180/110 mmHg), assessed by 24-hour ambulatory blood pressure monitoring (ABPM);
* cognitive deficit verified in the Mini Mental State Examination;
* diagnosis of Alzheimer's and Parkinson's.
65 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil
OTHER
Hospital de Clinicas de Porto Alegre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ruy S Moraes Filho, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital de Clínicas de Porto Alegre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-0529
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.